Payment overview · 2025
General Payments
$1,187.23
75 reported records · 21 companies
Healthcare provider profile · identity verified
Alanna E Angel, MD PHD
Allopathic & Osteopathic Physicians|Family Medicine · DUE WEST, SC · NPI 1124005541
Verified facts
What the public records show
CMS Open Payments records show Alanna E Angel, MD PHD received $1,187.23 in general payments during 2025 across 75 reported records.
ABBVIE INC. accounted for 16.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $193.02 | 16.3% | 14 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $165.96 | 14.0% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $141.33 | 11.9% | 11 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $101.49 | 8.6% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $97.15 | 8.2% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $72.13 | 6.1% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $65.57 | 5.5% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $42.10 | 3.5% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $36.25 | 3.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.67 | 2.8% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $30.20 | 2.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.30 | 2.4% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.77 | 2.3% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.49 | 2.0% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $23.47 | 2.0% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $22.72 | 1.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.53 | 1.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.73 | 1.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.14 | 1.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.48 | 1.2% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $13.73 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,187.23 | 75 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $165.96 | 10 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $101.49 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $97.15 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $91.93 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $91.93 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $72.13 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $70.89 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $62.11 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $55.70 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $54.31 | 6 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $46.78 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $46.03 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $36.25 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $34.33 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $31.24 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $31.24 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $30.20 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $27.92 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $27.92 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $27.77 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.49 | 1 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $23.47 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $22.72 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.53 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.14 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $16.14 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.14 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.48 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.18 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.18 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $13.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 41 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 59 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 25 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
59 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
59 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
108 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
25 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
41 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
29 | 29 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 328 | 103 |
| Atorvastatin Calcium | Atorvastatin Calcium | 311 | 84 |
| Levothyroxine Sodium | Levothyroxine Sodium | 263 | 66 |
| Omeprazole | Omeprazole | 225 | 63 |
| Furosemide | Furosemide | 208 | 49 |
| Gabapentin | Gabapentin | 181 | 50 |
| Amlodipine Besylate | Amlodipine Besylate | 179 | 55 |
| Tramadol Hcl | Tramadol Hcl | 167 | 39 |
| Lisinopril | Lisinopril | 166 | 55 |
| Losartan Potassium | Losartan Potassium | 161 | 46 |
| Zolpidem Tartrate | Zolpidem Tartrate | 148 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 147 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 143 | 46 |
| Lorazepam | Lorazepam | 134 | 28 |
| Prednisone | Prednisone | 133 | 85 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 132 | 25 |
| Metformin Hcl | Metformin Hcl | 129 | 38 |
| Clonazepam | Clonazepam | 128 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 126 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 120 | 37 |
| Mirtazapine | Mirtazapine | 117 | 29 |
| Meloxicam | Meloxicam | 116 | 52 |
| Mounjaro | Tirzepatide | 108 | 24 |
| Famotidine | Famotidine | 106 | 27 |
| Potassium Chloride | Potassium Chloride | 106 | 30 |
| Trazodone Hcl | Trazodone Hcl | 103 | 33 |
| Sertraline Hcl | Sertraline Hcl | 101 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 98 | 30 |
| Montelukast Sodium | Montelukast Sodium | 95 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 94 | 27 |
| Fluconazole | Fluconazole | 84 | 44 |
| Memantine Hcl | Memantine Hcl | 84 | 12 |
| Buspirone Hcl | Buspirone Hcl | 83 | 24 |
| Ezetimibe | Ezetimibe | 81 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 81 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 79 | 29 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 79 | 64 |
| Baclofen | Baclofen | 78 | 27 |
| Nystatin | Nystatin | 78 | 35 |
| Bupropion Xl | Bupropion Hcl | 77 | 25 |
| Alprazolam | Alprazolam | 73 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 69 | 11 |
| Allopurinol | Allopurinol | 68 | 15 |
| Ondansetron Odt | Ondansetron | 66 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 64 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 59 | 17 |
| Jardiance | Empagliflozin | 59 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 58 | 19 |
| Divalproex Sodium | Divalproex Sodium | 58 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 58 | 18 |
| Estradiol | Estradiol | 57 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 56 | 26 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 56 | 46 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 29 |
| Alendronate Sodium | Alendronate Sodium | 54 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 52 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 15 |
| Spironolactone | Spironolactone | 51 | 18 |
| Cephalexin | Cephalexin | 45 | 33 |
| Paroxetine Hcl | Paroxetine Hcl | 45 | 14 |
| Naproxen | Naproxen | 44 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | suppressed |
| Eliquis | Apixaban | 41 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 41 | 15 |
| Carvedilol | Carvedilol | 40 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 40 | suppressed |
| Chlorthalidone | Chlorthalidone | 39 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 24 |
| Risperidone | Risperidone | 33 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 33 | suppressed |
| Amoxicillin | Amoxicillin | 32 | 28 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 32 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 32 | 11 |
| Pregabalin | Pregabalin | 32 | suppressed |
| Azithromycin | Azithromycin | 31 | 23 |
| Myrbetriq | Mirabegron | 31 | 12 |
| Simvastatin | Simvastatin | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 29 | 29 |
| Finasteride | Finasteride | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Armour Thyroid | Thyroid,pork | 27 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 26 | suppressed |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Ozempic | Semaglutide | 25 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | 13 |
| Bumetanide | Bumetanide | 17 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Xifaxan | Rifaximin | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 14 | 14 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Banzel | Rufinamide | 13 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Galantamine Er | Galantamine Hbr | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Letrozole | Letrozole | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Tirosint | Levothyroxine Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,187.23 · 75 records | ABBVIE INC. | AIRSUPRA, AREXVY, CREON, CeQur Simplicity, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, Korlym, LEQVIO, LINZESS, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PENMENVY, PROLIA, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRINTELLIX, The Cologuard Plus Collection Kit, UBRELVY, VIVITROL, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error